MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

7.090 UNCHANGED
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,021,191
Open 7.070
Bid (Size) 7.020 (200)
Ask (Size) 7.180 (1,100)
Prev. Close 7.090
Today's Range 7.031 - 7.175
52wk Range 6.180 - 17.23
Shares Outstanding 259,965,579
Dividend Yield 1.13%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
Why Organon (OGN) Shares Are Trading Lower Today
Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new... 
Via StockStory
Topics Initial Public Offering

Performance

YTD
-52.6%
-52.6%
1 Month
+0.4%
+0.4%
3 Month
-31.9%
-31.9%
6 Month
-29.1%
-29.1%
1 Year
-51.9%
-51.9%

More News

Read More
News headline image
3 Stocks Under $10 We Steer Clear Of
Via StockStory
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
A Look at Organon's Upcoming Earnings Report ↗
Via Benzinga
News headline image
3 Value Stocks with Questionable Fundamentals
Via StockStory
News headline image
3 Cash-Producing Stocks We Find Risky
Via StockStory
News headline image
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks
News headline image
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
News headline image
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
From Organon & Co.
Via Business Wire
News headline image
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Organon (OGN) Stock Trades Down, Here Is Why
Via StockStory
Topics Artificial Intelligence Initial Public Offering Supply Chain
News headline image
Organon Analysts Cut Their Forecasts Following Q3 Results ↗
Via Benzinga
News headline image
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration
Via StockStory
News headline image
Organon Cuts 2025 Sales Outlook Despite Earnings Beat ↗
Via Benzinga
News headline image
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3
Via StockStory
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Via Benzinga
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon (OGN) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
From Organon & Co.
Via Business Wire
News headline image
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
From Organon & Co.
Via Business Wire
News headline image
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
From Organon & Co.
Via Business Wire
News headline image
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
Via StockStory

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 7.090
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 12/24/25 05:00 PM ET
What is the market capitalization of Organon & Co. Common Stock?
The market capitalization of Organon & Co. Common Stock is 1.84B
How many shares of Organon & Co. Common Stock are outstanding?
Organon & Co. Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story